Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Follow-Up Questions
Qui est le CEO de Aditxt Inc ?
Mr. Amro Albanna est le Chairman of the Board de Aditxt Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action ADTX ?
Le prix actuel de ADTX est de $0.2439, il a increased de 13.39% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Aditxt Inc ?
Aditxt Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Aditxt Inc ?
La capitalisation boursière actuelle de Aditxt Inc est de $1.2M
Est-ce que Aditxt Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Aditxt Inc, y compris 2 achat fort, 4 achat, 2 maintien, 0 vente et 2 vente forte
